Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Nahrain Schumaier

Cornea and External Diseases Specialist Chicago, IL Medical Doctor

NPI 1871175828 CMS profile 9229962

259 E Erie St Ste 1520, Chicago, IL 60611

Open in the dashboard

General payments

$2,645

46 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nahrain Schumaier of Chicago, IL is reported in the CMS Open Payments database as having received $2,645 across 46 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 63rd percentile of Cornea and External Diseases Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $554 9
2024 General $705 14
2023 General $848 10
2022 General $538 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nahrain Schumaier
  • Cornea and External Diseases Specialist median
  • Middle half of Cornea and External Diseases Specialist
  • National median

In program year 2025, general payments to Nahrain Schumaier were reported at $554. Among 290 Cornea and External Diseases Specialist profiles paid that year, the median was $477 and the middle half received between $193 and $1,174.

Show as a table
Year Nahrain Schumaier Cornea and External Diseases Specialist median Middle half National median
2019 $0 $276 $111–$734 $163
2020 $0 $146 $48–$330 $114
2021 $0 $254 $116–$566 $132
2022 $538 $251 $106–$729 $149
2023 $848 $344 $149–$759 $160
2024 $705 $366 $170–$927 $164
2025 $554 $477 $193–$1,174 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Alcon Vision LLC $933 14 payments
  2. Johnson & Johnson Surgical Vision, Inc. $605 15 payments
  3. AbbVie, Inc. $348 3 payments
  4. Sight Sciences, Inc. $218 4 payments
  5. Kerecis Limited $125 1 payment
  6. Horizon Therapeutics plc $125 1 payment
  7. Bausch & Lomb Americas Inc. $94 3 payments
  8. Carl Zeiss Meditec USA, Inc. $80 3 payments
  9. Genentech, Inc. $73 1 payment
  10. New World Medical,Inc. $46 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $2,545 45 payments
  2. Education $100 1 payment
Products named General payments · program years 2022–2025
  1. Centurion $365 4 payments
  2. LIPIFLOW SYSTEM ACTIVATOR (DISPOSABLE) $262 1 payment
  3. LIPIFLOW SYSTEM ACTIVATOR II (DISPOSABLE $262 1 payment
  4. MEIBOMIAN GLAND EVALUATOR $262 1 payment
  5. LIPIVIEW OCULAR SURFACE INTERFEROMETER $262 1 payment
  6. Clareon $255 4 payments
  7. HYDRUS Microstent $253 3 payments
  8. OMNI SURGICAL SYSTEM $181 3 payments
  9. Kerecis Omega3 SurgiClose $125 1 payment
  10. Kerecis Omega3 Marigen $125 1 payment
  11. Other $1,791 42 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

314

Median for Ophthalmology: 891

Drug cost

$8,978

Median for Ophthalmology: $68,233

Branded share of claims

17.8%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Prednisolone Acetate Generic 80 $4,211
Latanoprost Generic 73 $1,091
Ofloxacin Generic 49 $898
Brimonidine Tartrate Generic 32 $896
Valacyclovir Valacyclovir Hcl Brand 11 $842
Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat Brand 22 $413
Erythromycin Erythromycin Base Brand 23 $320
Timolol Maleate Generic 24 $307

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VABYSMO
  • Genentech, Inc. $73
$73 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

46 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cornea and External Diseases Specialist in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record